- Home
- CANF vs GORV Comparison
CANF vs GORV Comparison
Compare CANF & GORV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- GORV
- Stock Information
- Founded
- CANF 1994
- GORV 1976
- Country
- CANF Israel
- GORV United States
- Employees
- CANF N/A
- GORV N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- GORV Retail-Auto Dealers and Gas Stations
- Sector
- CANF Health Care
- GORV Consumer Discretionary
- Exchange
- CANF Nasdaq
- GORV Nasdaq
- Market Cap
- CANF 14.4M
- GORV 16.2M
- IPO Year
- CANF N/A
- GORV 2015
- Fundamental
- Price
- CANF $2.01
- GORV $0.93
- Analyst Decision
- CANF Strong Buy
- GORV Hold
- Analyst Count
- CANF 2
- GORV 2
- Target Price
- CANF $14.00
- GORV $2.00
- AVG Volume (30 Days)
- CANF 63.2K
- GORV 847.1K
- Earning Date
- CANF 11-26-2024
- GORV 11-18-2024
- Dividend Yield
- CANF N/A
- GORV N/A
- EPS Growth
- CANF N/A
- GORV N/A
- EPS
- CANF N/A
- GORV N/A
- Revenue
- CANF $667,000.00
- GORV $920,774,000.00
- Revenue This Year
- CANF $409.56
- GORV N/A
- Revenue Next Year
- CANF N/A
- GORV $6.13
- P/E Ratio
- CANF N/A
- GORV N/A
- Revenue Growth
- CANF N/A
- GORV N/A
- 52 Week Low
- CANF $1.87
- GORV $0.88
- 52 Week High
- CANF $4.69
- GORV $8.15
- Technical
- Relative Strength Index (RSI)
- CANF 38.15
- GORV 40.12
- Support Level
- CANF $1.93
- GORV $0.79
- Resistance Level
- CANF $2.21
- GORV $1.96
- Average True Range (ATR)
- CANF 0.20
- GORV 0.24
- MACD
- CANF -0.02
- GORV -0.00
- Stochastic Oscillator
- CANF 15.52
- GORV 13.59
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.